|MerLion Pharmaceuticals||Finafloxacin||Oncology & Anti-infectives & Vaccines - Helicobacter pylori antibiotic (linked to gastric ulceration and gastric cancer)||pH activated antibiotic|
|Affibody||Her-2 Affibody||Oncology - breast cancer||Antibody alternative that is tagged by a radionuclide and so can be used as targeted therapy or diagnostic - the latter being the case with this trial|
|Biotie & Roche||undisclosed||Inflammation||Human Vascular Adhesion Protein-1 (VAP-1) monoclonal antibody|
|Pharmacopeia & Schering-Plough||PS948115||respiratory disease||undisclosed|
|VaxInnate Corporation||M2e vaccine||Anti-infectives & Vaccines - influenza||Targets the M2 ectodomain (M2e) portion of the flu virus, which is inherent regardless of virus strain|
|University of Alberta||dichloroacetate||Oncology - glioblastoma||Dichloroacetate (DCA) retores mitochondrial function, thus restoring apoptosis. Phase II trial approved by Health Canada, but no Phase I ever been done. Develpoed privately as moelcule can't be patented|
The latest in a series of periodic roundups of drugs that have moved from preclinical research into clinical testing via the announcement of a Phase I trial or an application for a trial to industry regulators.